D.A. Davidson & Co. Red Hill Biopharma Ltd. Transaction History

D.A. Davidson & Co.

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 07, 2022	SELL	$0.5 - $523.8 $2,000 - $2.1 Million	-4,000 Reduced 27.59%	10,500 $5,000
Q2 2022 Jul 28, 2022	SELL	$0.63 - $2.58 $1,449 - $5,934	-2,300 Reduced 13.69%	14,500 $13,000
Q3 2021 Nov 15, 2021	SELL	$4.55 - $10.36 $59,150 - $134,680	-13,000 Reduced 43.62%	16,800 $77,000
Q4 2020 Feb 10, 2021	BUY	$7.81 - $10.39 $82,005 - $109,095	10,500 Added 54.4%	29,800 $241,000
Q3 2020 Nov 02, 2020	BUY	$6.34 - $10.83 $17,752 - $30,324	2,800 Added 16.97%	19,300 $197,000
Q2 2020 Aug 10, 2020	BUY	$4.6 - $8.6 $25,299 - $47,300	5,500 Added 50.0%	16,500 $111,000
Q1 2020 May 05, 2020	BUY	$3.51 - $6.17 $38,610 - $67,870	11,000 New	11,000 $50,000
Q4 2019 Feb 14, 2020	SELL	$5.76 - $7.35 $142,560 - $181,912	-24,750 Closed	0 $0
Q3 2019 Nov 05, 2019	SELL	$6.46 - $8.37 $6,460 - $8,370	-1,000 Reduced 3.88%	24,750 $174,000
Q2 2019 Aug 13, 2019	SELL	$6.34 - $8.8 $33,285 - $46,200	-5,250 Reduced 16.94%	25,750 $167,000
Q4 2018 Jan 29, 2019	SELL	$5.18 - $9.35 $12,950 - $23,375	-2,500 Reduced 7.46%	31,000 $172,000
Q2 2018 Aug 02, 2018	BUY	$4.82 - $8.53 $9,640 - $17,060	2,000 Added 6.35%	33,500 $286,000
Q1 2018 May 04, 2018	SELL	$4.96 - $6.84 $37,200 - $51,300	-7,500 Reduced 19.23%	31,500 $162,000
Q4 2017 Feb 08, 2018	SELL	$4.58 - $10.81 $22,900 - $54,050	-5,000 Reduced 11.36%	39,000 $200,000
Q2 2017 Aug 11, 2017	BUY	N/A	44,000	44,000 $0

40.4K

Ticker RDHL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 63,823,500
Market Cap $465M
Description
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for...

Get notified when there are updates to the investment portfolio of D.A. Davidson & Co., based on Form 13F filings with the SEC.

Stay updated on D.A. Davidson & Co. with notifications on news.